Search Results - "Cunningham, Lea C"

FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease by Przepiorka, Donna, Luo, Lola, Subramaniam, Sriram, Qiu, Junshan, Gudi, Ramadevi, Cunningham, Lea C., Nie, Lei, Leong, Ruby, Ma, Lian, Sheth, Christopher, Deisseroth, Albert, Goldberg, Kirsten B., Blumenthal, Gideon M., Pazdur, Richard

“…On May 24, 2019, the Food and Drug Administration approved ruxolitinib for steroid‐refractory acute graft‐versus‐host disease (SR‐aGVHD) in adult and pediatric…”
Get full text

Acute Kidney Injury in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation: Incidence, Risk Factors, and Outcomes by Koh, Kyung-Nam, Sunkara, Anusha, Kang, Guolian, Sooter, Amanda, Mulrooney, Daniel A., Triplett, Brandon, Onder, Ali Mirza, Bissler, John, Cunningham, Lea C.

“…•Acute kidney injury is common after hematopoietic cell transplantation in children.•Survival is poor among patients with stage 3 acute kidney injury.•Survival…”
Get full text

An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia by Sinha, Chandrima, Cunningham, Lea C.

“…Patients with acute myeloid leukemia (AML) have relatively low survival rates compared to patients with other pediatric cancers. Relapse is frequent with…”
Get full text

Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities by Sinha, Chandrima, Cunningham, Lea C, Liu, Paul P

“…Core binding factor (CBF) is a heterodimeric protein complex involved in the transcriptional regulation of normal hematopoiesis. Mutations in CBF-encoding…”
Get full text

Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion syndrome by Mussai, Francis J, Cunningham, Lea C, Rezvani, Geoffrey, Stratakis, Constantine A, Reynolds, James C, Nesterova, Galina, Henshaw, Robert M, Levine, Jason E, Helman, Lee J, Arthur, Diane C, Kim, Su Young

“…Hypocalcemia is a rare complication of osteosarcoma, having been described in only 4 reports. We present the case of a 16-year-old male with metastatic…”
Get full text

Genomic Landscape of RUNX1-Familial Platelet Disorder with Myeloid Malignancies Reveals Rising Clonal Hematopoiesis by Yu, Kai, Merguerian, Matthew, Deuitch, Natalie, Bresciani, Erica, Davis, Joie, Craft, Kathleen, Cunningham, Lea C., Liu, Paul P.

“…Familial platelet disorder with associated myeloid malignancies (FPDMM) is a rare autosomal dominant disease caused by germline RUNX1 mutations. FPDMM patients…”
Get full text

Fr139 GASTROINTESTINAL DISEASE IN PATIENTS WITH FAMILIAL PLATELET DISORDER WITH ASSOCIATED MYELOID MALIGNANCY by Bhattacharya, Sumona, Passi, Monica, Merguerian, Matthew D., Craft, Kathleen, Hadigan, Colleen, Davis, Joie, Liu, Paul, Cunningham, Lea C., Heller, Theo

Get full text

SWI/SNF Chromatin Remodeling Complex Regulates the Expression of PD-L1 in a Spatio-Temporal Manner in Acute Lymphoblastic Leukemia (ALL) in Vitro by Kahali, Bhaskar, Sinha, Chandrima, Ritter, Abby, Cunningham, Lea C.

“…Epigenetic changes and interactions between different cells within the tumor microenvironment are critical for the maintenance and progression of cancer. The…”
Get full text

An Evaluation of the Cytotoxic Effect of the Natural Product Aaptamine Against t(4;11) Leukemias by Sinha, Chandrima, Bowling, John, Seth, Aman, Ju, Bensheng, Kahali, Bhaskar, Hamann, Mark, Cunningham, Lea C.

“…The marine environment has been shown to be a rich source of pharmacologically-active secondary metabolites. Three marine- compounds have FDA approval for…”
Get full text

"CRACK," STREET GANGS, AND VIOLENCE by KLEIN, MALCOLM W., MAXSON, CHERYL L., CUNNINGHAM, LEA C.

“…This investigation considers the connections among street gangs, “crack” cocaine, and violence associated with crack distribution during the initial years of…”
Get full text

Core binding factor AML: New prognostic categories and therapeutic opportunities by Sinha, Chandrima, Cunningham, Lea C., Liu, Paul P.

“…Core binding factor (CBF) is a heterodimeric protein complex involved in the transcriptional regulation of normal hematopoiesis. Mutations in CBF-encoding…”
Get full text

FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease by Przepiorka, Donna, Luo, Lola, Subramaniam, Sriram, Qiu, Junshan, Gudi, Ramadevi, Cunningham, Lea C, Nie, Lei, Leong, Ruby, Ma, Lian, Sheth, Christopher, Deisseroth, Albert, Goldberg, Kirsten B, Blumenthal, Gideon M, Pazdur, Richard

“…On May 24, 2019, the Food and Drug Administration approved ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in adult and pediatric…”
Get full text